## AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):

$$\begin{array}{c} \mathbb{R}^{7} \text{OH} \\ \mathbb{Q} \\$$

wherein R7 and R21 are the same or are different and represent

-O-benzoyl,

[[OH,]] or

RC(=Y)-O-, wherein Y represents an oxygen atom, and R represents

piperazinył 4-alkyl-piperazin-1-yl, alkyl, -O-phenyl, -N-alkyl -N,N-dialkyl or -

NH-phenyl, or

a pharmacologically acceptable salt thereof.

 (Currently Amended) [[The]] A compound according to claim-1 represented by the formula (I-a):

wherein R7a and R21a are the same or are different and represent

RaC(=Ya)-O-, wherein Ya represents an oxygen atom, and Ra represents

a C1 to C22 alkyl group,

an unsaturated C2 to C22 alkyl group,

a C3 to C14 cycloalkyl group

or a pharmacologically acceptable salt thereof.

3-18. (Canceled).

19. (Previously Presented) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide,
(8E,12E,14E)-21-(N,N-dimethylcarbamoyloxy)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricosa-8,12,14-trien-11-olide, and
(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricosa-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof.

Application No. 10/522,733 Docket No.: 0152-0701PUS1 Supplemental Amendment

20. (Canceled).

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Canceled).